{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:11:01Z","timestamp":1789593061079,"version":"build-2803163510"},"reference-count":130,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Therapeutic cancer vaccines have emerged as a promising approach in cancer immunotherapy, aiming to stimulate the immune system to recognize and eliminate malignant cells. Despite this potential, clinical efficacy has remained variable across multiple vaccine platforms. This review synthesizes completed clinical trials evaluating major therapeutic cancer vaccine modalities, including peptide-based, nucleic acid--based, dendritic cell, whole cell, and viral and bacterial vector--based vaccines, with a focus on safety, immunogenicity, and clinical outcomes for diverse tumor types. Overall, these vaccines demonstrate a favorable safety profile; however, clinical efficacy as monotherapy has been limited. Clinical outcomes vary by platform and tumor type and are influenced by factors such as antigen selection, tumor heterogeneity and immunosuppressive tumor microenvironment (TME). Recent advances in antigen design, vaccine technologies, and combination strategies are redefining the role of therapeutic cancer vaccines in oncology. Future progress will depend on optimizing their integration with standard treatment modalities, particularly immune checkpoint inhibitors.<\/jats:p>","DOI":"10.3390\/vaccines14070599","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:04:49Z","timestamp":1783411489000},"page":"599","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Cancer Vaccines: Mechanisms, Clinical Progress, and Future Directions"],"prefix":"10.3390","volume":"14","author":[{"given":"Kendra","family":"Wilson","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Medical Oncology, University of Texas at Tyler School of Medicine, 11937 US-271, Tyler, TX 75708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus Salvador","family":"Flores Banda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Oncology, SUNY Downstate Health Sciences University, 445 Lenox Rd., Brooklyn, NY 11203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Bukkapatnam","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Roswell Park Comprehensive Cancer Center, 665 Elm St., Buffalo, NY 14203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Raza","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Medical Oncology, University of Texas at Tyler School of Medicine, 11937 US-271, Tyler, TX 75708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminia","family":"Massarelli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Medical Oncology, University of Texas at Tyler School of Medicine, 11937 US-271, Tyler, TX 75708, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1158\/1055-9965.EPI-19-1534","article-title":"Medical Care Costs Associated with Cancer Survivorship in the United States","volume":"29","author":"Mariotto","year":"2020","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40425-015-0072-2","article-title":"Tumor immunology and cancer immunotherapy: Summary of the 2014 SITC primer","volume":"3","author":"Page","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41423-025-01316-4","article-title":"Eliciting antitumor immunity via therapeutic cancer vaccines","volume":"22","author":"Peng","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Rameshbabu, S., Labadie, B.W., Argulian, A., and Patnaik, A. (2021). Targeting Innate Immunity in Cancer Therapy. Vaccines, 9.","DOI":"10.3390\/vaccines9020138"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.cell.2024.03.037","article-title":"Principles and therapeutic applications of adaptive immunity","volume":"187","author":"Chi","year":"2024","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(25)00553-7","article-title":"Cancer vaccines and the future of immunotherapy","volume":"406","author":"Pail","year":"2025","journal-title":"Lancet"},{"key":"ref_8","unstructured":"Rout, P., Caminero, F., Iqbal, Z., and Tadi, P. (2023). Histology, Cytotoxic T Cells. StatPearls, StatPearls Publishing. Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559279\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","article-title":"Biological and therapeutic impact of intratumor heterogeneity in cancer evolution","volume":"27","author":"McGranahan","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1200\/JCO.2002.09.134","article-title":"Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings","volume":"20","author":"Belli","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(08)60697-2","article-title":"An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial","volume":"372","author":"Wood","year":"2008","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4161\/hv.20740","article-title":"Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer","volume":"8","author":"Hanna","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/1078-0432.CCR-03-0071","article-title":"Phase II Randomized Trial of Autologous Formalin-Fixed Tumor Vaccine for Postsurgical Recurrence of Hepatocellular Carcinoma","volume":"10","author":"Kuang","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/1097-0142(19851101)56:9<2194::AID-CNCR2820560910>3.0.CO;2-L","article-title":"The Serologic Response of Patients with Stage II Melanoma to Allogeneic Melanoma Cell Vaccines","volume":"56","author":"Liveingston","year":"1985","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4161\/hv.26568","article-title":"Allogeneic tumor cell vaccines: The promise and limitations in clinical trials","volume":"10","author":"Srivatsan","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.ejca.2015.07.035","article-title":"A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer","volume":"51","author":"Giaccone","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"MMAIT-IV Clinical Trial Group, Faries, M.B., Mozzillo, N., Kashani-Sabet, M., Thompson, J.F., Kelley, M.C., DeConti, R.C., Lee, J.E., Huth, J.F., and Wagner, J. (2017). Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. Ann. Surg. Oncol., 24, 3991\u20134000.","DOI":"10.1245\/s10434-017-6072-3"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","article-title":"A Phase 2 Study of Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-21-1916","article-title":"An allogeneic multiple myeloma GM-CSF-secreting vaccine with lenalidomide induces long-term immunity and durable clinical responses in patients in near complete remission","volume":"27","author":"Biavati","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1034\/j.1600-065X.2002.18813.x","article-title":"GM-CSF-based cancer vaccines","volume":"188","author":"Dranoff","year":"2002","journal-title":"Immunol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2337s","DOI":"10.1158\/1078-0432.CCR-05-2555","article-title":"Allogeneic and Autologous Melanoma Vaccines: Where Have We Been and Where Are We Going?","volume":"12","author":"Sondak","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1084\/jem.137.5.1142","article-title":"Identification of a Novel Cell Type in Peripheral Lymphoid Organs of Mice: I. Morphology, Quantitation, Tissue Distribution","volume":"137","author":"Steinman","year":"1973","journal-title":"J. Exp. Med."},{"key":"ref_24","first-page":"17","article-title":"Dendritic cells: Translating innate to adaptive immunity","volume":"311","author":"Steinman","year":"2006","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_25","first-page":"1099","article-title":"Generation of Immunostimulatory Dendritic Cells from Human CD34+ Hematopoietic Progenitor Cells of the Bone Marrow And Peripheral Blood","volume":"55","author":"Bernhard","year":"1995","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/sj.bmt.1702525","article-title":"Dendritic cells can be successfully generated from CD34+ cord blood cells in the presence of autologous cord blood plasma","volume":"26","author":"Matthews","year":"2000","journal-title":"Bone Marrow Transpl."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Salvi","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gi, M., Im, W., and Hong, S. (2009). Dendritic Cells as Danger-Recognizing Biosensors. Sensors, 9.","DOI":"10.3390\/s90906730"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lee, K.W., Yam, J.W.P., Lee, K.W., Wai, J., Yam, P., and Mao, X. (2023). Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations. Cells, 12.","DOI":"10.3390\/cells12172147"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Dobosz, P., and Dzieci\u0105tkowski, T. (2019). The Intriguing History of Cancer Immunotherapy. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02965"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients with Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e21561","DOI":"10.1200\/JCO.2024.42.16_suppl.e21561","article-title":"Dendritic cell vaccine as a strategy to prevent melanoma recurrence after local resection: A systematic review and meta-analysis","volume":"42","author":"Silva","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41467-024-45358-0","article-title":"Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: The MIND-DC randomized phase III trial","volume":"15","author":"Bol","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-1-0716-4542-0_4","article-title":"Dendritic Cell Cancer Vaccines: A Focused Review","volume":"2926","author":"Maeng","year":"2025","journal-title":"Methods Mol. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-15-1399","article-title":"Dendritic Cell-Based Immunotherapy: State of the Art and Beyond","volume":"22","author":"Bol","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/fon.12.125","article-title":"Dendritic cell-based vaccines: Barriers and opportunities","volume":"8","author":"Cintolo","year":"2012","journal-title":"Future Oncol."},{"key":"ref_38","first-page":"1643","article-title":"Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma","volume":"254","author":"Traversari","year":"1991","journal-title":"Science (1979)"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ijc.2910630622","article-title":"Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES-3","volume":"63","author":"Marchand","year":"1995","journal-title":"Int. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: Promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3892\/ol.2022.13208","article-title":"Neoantigens and their potential applications in tumor immunotherapy","volume":"23","author":"Fang","year":"2022","journal-title":"Oncol. Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10238-024-01436-7","article-title":"Personalized neoantigen cancer vaccines: Current progression, challenges and a bright future","volume":"24","author":"Wu","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_43","first-page":"9749363","article-title":"Development of Peptide-Based Vaccines for Cancer","volume":"2022","author":"Poh","year":"2022","journal-title":"J. Oncol."},{"key":"ref_44","first-page":"43","article-title":"Cancer Neoantigens","volume":"37","author":"Schumacher","year":"2026","journal-title":"Annu. Rev. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Lu, M., Qin, Y., Gao, W., Tao, L., Su, W., and Zhong, J. (2021). Neoantigen: A New Breakthrough in Tumor Immunotherapy. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.672356"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"ref_48","unstructured":"(2026, February 23). Study Details|NCT05269381|Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for Treatment of Advanced Solid Tumors|ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05269381."},{"key":"ref_49","unstructured":"(2026, February 23). Study Details|NCT04183166|A Clinical Trial Evaluating TG4050 in Head and Neck Cancer|ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04183166."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1200\/JCO.2025.43.16_suppl.6016","article-title":"Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts)","volume":"43","author":"Delord","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PPO.0b013e318233e5b2","article-title":"The Present and Future of Peptide Vaccines for Cancer: Single or Multiple, Long or Short, Alone or in Combination?","volume":"17","author":"Slingluff","year":"2011","journal-title":"Cancer J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14760584.2021.1935248","article-title":"Challenges targeting cancer neoantigens in 2021: A systematic literature review","volume":"20","author":"Chen","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"168297","DOI":"10.1016\/j.jmb.2023.168297","article-title":"DNA Vaccines: History, Molecular Mechanisms and Future Perspectives","volume":"435","author":"Pagliari","year":"2023","journal-title":"J. Mol. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11478","DOI":"10.1073\/pnas.90.24.11478","article-title":"DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations","volume":"90","author":"Fynan","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1128\/jvi.67.9.5664-5667.1993","article-title":"Bovine herpesvirus 1: Immune responses in mice and cattle injected with plasmid DNA","volume":"67","author":"Cox","year":"1993","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1128\/jvi.69.4.2574-2582.1995","article-title":"DNA vaccination against persistent viral infection","volume":"69","author":"Martins","year":"1995","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"(2021). Moderna feud with NIH over COVID vaccine. Nat. Biotechnol., 39, 1481.","DOI":"10.1038\/s41587-021-01166-1"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct Gene Transfer into Mouse Muscle in Vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","article-title":"Cancer DNA vaccines: Current preclinical and clinical developments and future perspectives","volume":"38","author":"Lopes","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","article-title":"Electroporation Delivery of DNA Vaccines: Prospects for Success","volume":"23","author":"Sardesai","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1073\/pnas.96.8.4262","article-title":"High-efficiency gene transfer into skeletal muscle mediated by electric pulses","volume":"96","author":"Mir","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.4161\/onci.22563","article-title":"HER2\/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: Gene gun is superior to jet injector in inducing CTL responses and protective immunity","volume":"1","author":"Kobelt","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.19.01701","article-title":"Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer","volume":"37","author":"McNeel","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1200\/JCO.2008.19.9968","article-title":"Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer","volume":"27","author":"McNeel","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e008067","DOI":"10.1136\/jitc-2023-008067","article-title":"Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer","volume":"11","author":"McNeel","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12929-024-01102-w","article-title":"Advances in nucleic acid-based cancer vaccines","volume":"32","author":"Liao","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"ref_67","unstructured":"(2026, January 26). The Long History of mRNA Vaccines|Johns Hopkins|Bloomberg School of Public Health. Available online: https:\/\/publichealth.jhu.edu\/2021\/the-long-history-of-mrna-vaccines."},{"key":"ref_68","unstructured":"(2026, January 26). FDA Approves First COVID-19 Vaccine|F.D.A, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-covid-19-vaccine."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00262-025-03992-7","article-title":"Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model","volume":"74","author":"Nguyen","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/s41467-025-57149-2","article-title":"LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment","volume":"16","author":"Xue","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/CJI.0b013e31815ce501","article-title":"Results of the first phase I\/II clinical vaccination trial with direct injection of mRNA","volume":"31","author":"Weide","year":"2008","journal-title":"J. Immunother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"38138","DOI":"10.1038\/s41598-025-21924-4","article-title":"Immunomodulatory vaccine demonstrates therapeutic efficacy across cancer types","volume":"15","author":"Han","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref_76","unstructured":"Balachandran, V.P. (2026, January 17\u201322). Personalized mRNA neoantigen vaccine (autogene cevumeran; BNT122\/RO7198457). Proceedings of the AACR Annual Meeting 2026, San Diego, CA, USA."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: A phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/humc.2015.2524","article-title":"Mutanome Engineered RNA Immunotherapy (MERIT)","volume":"26","author":"Sahin","year":"2015","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"101430","DOI":"10.1016\/j.smim.2020.101430","article-title":"New viral vectors for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/j.vaccine.2016.04.060","article-title":"Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains","volume":"34","author":"Condit","year":"2016","journal-title":"Vaccine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/PPO.0b013e3182325e63","article-title":"Viral Vector -based Therapeutic Cancer Vaccines","volume":"17","author":"Larocca","year":"2011","journal-title":"Cancer J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ni.3123","article-title":"Control of adaptive immunity by the innate immune system","volume":"16","author":"Iwasaki","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nri3254","article-title":"Cross-presentation by dendritic cells","volume":"12","author":"Joffre","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4+ T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"djw261","DOI":"10.1093\/jnci\/djw261","article-title":"Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment","volume":"109","author":"Gulley","year":"2017","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: A randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: A single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"ABoorjian","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/BLC-230083","article-title":"The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward","volume":"10","author":"Steinmetz","year":"2024","journal-title":"Bladder Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu\u00e9rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J. Urol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"eaat7807","DOI":"10.1126\/scitranslmed.aat7807","article-title":"The hallmarks of successful anticancer immunotherapy","volume":"10","author":"Galluzzi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Yang, M., Zhong, P., and Wei, P. (2025). Living Bacteria: A New Vehicle for Vaccine Delivery in Cancer Immunotherapy. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26052056"},{"key":"ref_96","unstructured":"(2026, January 26). Coley\u2019s Toxin: Historical Perspective, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/12073431\/."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Thomas, C.J., Delgado, K., Sawant, K., Roy, J., Gupta, U., Song, C.S., Poojary, R., de Figueiredo, P., and Song, J. (2024). Harnessing Bacterial Agents to Modulate the Tumor Microenvironment and Enhance Cancer Immunotherapy. Cancers, 16.","DOI":"10.3390\/cancers16223810"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"18627","DOI":"10.1073\/pnas.2004421117","article-title":"Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-\u03b3 signaling","volume":"117","author":"Antonelli","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs. transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Galen, J.E., Buskirk, A.D., Tennant, S.M., and Pasetti, M.F. (2016). Live Attenuated Human Salmonella Vaccine Candidates: Tracking the Pathogen in Natural Infection and Stimulation of Host Immunity. EcoSal Plus, 7.","DOI":"10.1128\/ecosalplus.esp-0010-2016"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"16346","DOI":"10.1021\/acs.nanolett.5c03938","article-title":"Tumor-Targeted Bacterial Vaccine Induces In Situ Immunogenic Cell Death for Cancer Immunotherapy","volume":"25","author":"Wu","year":"2025","journal-title":"Nano Lett."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"10170","DOI":"10.1073\/pnas.0703867104","article-title":"Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer","volume":"104","author":"Zhao","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-23-0118","article-title":"Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies","volume":"29","author":"Luke","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"249ra111","DOI":"10.1126\/scitranslmed.3008982","article-title":"Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses","volume":"6","author":"Roberts","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer","volume":"33","author":"Le","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2350778","DOI":"10.1002\/eji.202350778","article-title":"Current advances in bacteria-based cancer immunotherapy","volume":"54","author":"Guo","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S1470-2045(20)30234-5","article-title":"Turning up the heat on non-immunoreactive tumours: Opportunities for clinical development","volume":"21","author":"Zimmermann","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ijc.31744","article-title":"Myeloid-derived suppressor cells: Roles in the tumor microenvironment and tumor radiotherapy","volume":"144","author":"Yin","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/imr.12982","article-title":"Cancer-associated fibroblasts: Key players in shaping the tumor immune microenvironment","volume":"302","author":"Desbois","year":"2021","journal-title":"Immunol. Rev."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/imm.13871","article-title":"Metabolic Reprogramming in Cancer: Implications for Immunosuppressive Microenvironment","volume":"174","author":"Aden","year":"2025","journal-title":"Immunology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"105336","DOI":"10.1016\/j.critrevonc.2026.105336","article-title":"Personalized neoantigen cancer vaccines: Why clinical benefit remains inconsistent","volume":"223","author":"Singh","year":"2026","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the breast tumor immune microenvironment: Cold-to-hot transition for enhanced immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.semcancer.2022.12.003","article-title":"Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines","volume":"88","author":"Oladejo","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"103095","DOI":"10.1016\/j.ctrv.2026.103095","article-title":"Personalized cancer vaccines and their integration with standard of care modalities","volume":"143","author":"Friedlaender","year":"2026","journal-title":"Cancer Treat. Rev."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"122290","DOI":"10.1016\/j.biomaterials.2023.122290","article-title":"Chemotherapy-induced nanovaccines implement immunogenicity equivalence for improving cancer chemoimmunotherapy","volume":"301","author":"Li","year":"2023","journal-title":"Biomaterials"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2219591","DOI":"10.1080\/2162402X.2023.2219591","article-title":"Trial watch: Chemotherapy-induced immunogenic cell death in oncology","volume":"12","author":"Sprooten","year":"2023","journal-title":"Oncoimmunology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e138740","DOI":"10.1172\/JCI138740","article-title":"Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control","volume":"131","author":"Lhuillier","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/ijc.32325","article-title":"Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment","volume":"145","author":"Koske","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1158\/0008-5472.CAN-24-2553","article-title":"Leveraging Artificial Intelligence for Neoantigen Prediction","volume":"85","author":"Zeng","year":"2025","journal-title":"Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Cai, Y., Chen, R., Gao, S., Li, W., Liu, Y., Su, G., Song, M., Jiang, M., Jiang, C., and Zhang, X. (2023). Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1054231"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e14639","DOI":"10.1200\/JCO.2025.43.16_suppl.e14639","article-title":"imNEO: High-accuracy neoantigen prediction through AI-based integrated analysis of multiple immunogenicity-related factors","volume":"43","author":"Cho","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Srivastava, R. (2026). AI-powered mapping of tumor immunity for optimized mRNA vaccine engineering. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1766201"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e21936","DOI":"10.1002\/advs.202521936","article-title":"Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy","volume":"13","author":"Wu","year":"2026","journal-title":"Adv. Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"19333","DOI":"10.1038\/s41598-025-01680-1","article-title":"Multi-omics and AI-driven immune subtyping to optimize neoantigen-based vaccines for colorectal cancer","volume":"15","author":"Vasudevan","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Kumar, A., Dixit, S., Srinivasan, K., M, D., and Vincent, P.D.R. (2024). Personalized cancer vaccine design using AI-powered technologies. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1357217"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s13402-026-01199-1","article-title":"Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy","volume":"49","author":"Li","year":"2026","journal-title":"Cell. Oncol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/599\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:09:30Z","timestamp":1783415370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/7\/599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":130,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["vaccines14070599"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14070599","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]}}}